MuGard Advocate Interviewed on ABC Tampa News at Noon

Investor Call to Be Held Today at 11:00am EST


DALLAS and NEW YORK, Dec. 7, 2011 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced that an oncology supportive care nurse, Michelle Devries, was interviewed this week on the WWSB-ABC Tampa News at Noon segment covering the common side effects of cancer treatments, specifically oral mucositis, and the positive clinical benefit seen when using MuGard.  In the interview, Devries provides insight to her experience with the debilitating effects of oral mucositis and debilitating effects of oral mucositis and references MuGard as the preferred treatment option for her and her patients. The interview can be viewed by clicking on the following link, http://youtu.be/K3QpFNRd47s.

Conference Call Details:

The investor conference call is scheduled to be this morning, Wednesday, December 7, 2011 at 11:00 am EST.  Interested parties may participate by dialing 877-407-4019 (US) or 201-689-8337 (International) approximately five to ten minutes before the call start time.

A replay of the call will be available starting on December 7th at 1:00 pm EST, through December 21, 2011 until 11:59 pm EST.  Interested parties may access the replay by dialing 877-660-6853 (US) or 201-612-7415 (International) and entering account number 383 and conference ID #383500.

About MuGard:

MuGard is a novel; ready-to-use mucoadhesive oral wound rinse and coating for the management of oral mucositis, a debilitating side effect of many anticancer treatments characterized by inflammation and ulceration of the mouth, tongue and throat. Up to 40% of all patients receiving chemotherapy and radiotherapy develop moderate to severe mucositis, and almost all patients receiving radiotherapy for head and neck cancer and those undergoing stem cell transplantation develop mucositis. Updated clinical practice guidelines for the prevention and treatment of mucositis recommend the use of a preventive oral care regimen as part of routine supportive care along with a therapeutic oral care regimen if mucositis develops. The market for the treatment of oral mucositis is estimated to be in excess of $1 billion world-wide.  For more information, please visit www.MuGard.com.

About Access:

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access' products include MuGard™ (www.MuGard.com), which has received FDA marketing clearance for the management of patients with mucositis, ProLindac™, a second generation DACH Platinum in Phase 2 clinical testing of patients with ovarian cancer, and Thiarabine™, a novel nucleoside analog that has demonstrated both pre-clinical and clinical activity in certain cancers; currently in a Phase 1/2a trial in hematological malignancies at M.D. Anderson Cancer Center in Houston, Texas. 

The company also has other advanced drug delivery technologies including CobaCyte™-mediated targeted delivery and CobOral-oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism.  For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our cash burn rate, clinical trial plans and timelines and clinical results for ProLindac, MuGard, Thiarabine and Cobalamin and other product candidates, our ability to achieve clinical and commercial success and our ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited to Access' need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access' Annual Reports on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.

Company and Media Contact:                               
                                                  Contact: Investor Relations
 
Christine Berni                                                      
                                                          Donald C. Weinberger
 
Director of Investor Relations                                   
                              Wolfe Axelrod Weinberger Assoc. LLC
 
Access Pharmaceuticals, Inc.                                  
                                                                    (212) 370-4500
 
(212) 786-6208
 
 
 

 

 


SOURCE Access Pharmaceuticals, Inc.

Posted: December 2011

View comments

Hide
(web3)